UC Irvine to Initiate Trial of Aviptadil as a COVID-19 Treatment

The University of California, Irvine (UCI) is launching a phase 2b/3 trial to evaluate aviptadil in COVID-19 patients with ARDS.

The trial will enroll up to 30 hospitalized patients at UCI Medical Center who have ARDS and require mechanical ventilation.

Aviptadil is a synthetic form of a human polypeptide that protects lung function. It has been used in trials for sarcoidosis, an inflammatory disease that attacks the lungs and lymph glands, as well as for pulmonary fibrosis and pulmonary hypertension.